Senate health committee Chair Bernie Sanders (I-VT) is demanding Novo Nordisk share communications about pricing, sales data and a range of other information as he doubles down on calls for the company to significantly cut what he calls “outrageously” high prices for its obesity and type-2 diabetes drugs, Wegovy and Ozempic. Sanders sent a letter Wednesday (April 24) asking Novo CEO Lars Fruergaard Jørgensen to answer six questions by May 8, as a part of his ongoing campaign to lower...